Georgia Politics & Government Online Community
In a state that has been reliably red in the last decade's worth of elections, this mid term Georgia Senate race has some newcomers that can really shake things up, and give an all important tally win, either red or blue, in the battleground for overall Senate control. Historically, its true that the President's party doesn't do well in the mid-terms.
Republican Georgia Governor Nathan Deal signed the "Safe Carry Protection Act" into state law on 4/23/2014. This law is being dubbed the "guns everywhere" bill by its critics. Here are the in's and out's of this incredibly controversial law, that goes into effect on July 1st.
Tuesday’s contest in Georgia’s 6th Congressional District to fill the seat of now-Health and Human Services Secretary Tom Price has gotten the president’s attention. He tweeted, “The super Liberal Democrat in the Georgia Congressioal [sic] race tomorrow wants to protect criminals, allow illegal immigration and raise taxes!” However unintentionally, this line of crude attack may well remind many upscale Republican and Democratic voters in this district why they dislike President Trump. He barely carried the district, running almost points behind Price in November. (NBC News finds: “Tom Price got 62% of the vote in this highly educated and affluent Atlanta-area district in 2016, and Mitt Romney took 61% in 2012. But Trump barely beat Hillary Clinton here in 2016, 48%-47%.”)
A key committee vote on Health and Human Services cabinet nominee, Rep. Tom Price, stalled Tuesday amid charges from Senate Democrats that he has misled the public about issues in his financial background. Democrats are demanding fuller explanations, and Republicans are vowing to break the committee impasse.
Georgia congressman John Lewis deployed a strategy from his days as a civil rights activist and the viral nature of social media to stage a dramatic sit-in Wednesday on the House floor with his fellow Democrats to force a vote on gun control.
Fifteen children have died from complications of the flu so far this season, the Centers for Disease Control and Prevention noted, as it officially declared the illness an epidemic. The number of states reporting a high amount of “influenza-like” illness activity has increased from 13 to 22 since last week’s report from the agency, with outbreaks in every region of the country.
A laboratory technician for the U.S. Centers for Disease Control and Prevention has been placed under observation for possible exposure to the deadly Ebola virus due to an apparent mix-up in lab specimens, the Atlanta-based agency said on Wednesday. The technician, who was working on Monday with Ebola specimens that were supposed to have been inactivated but which may instead have contained live virus, will be monitored for signs of infection for 21 days, the disease's incubation period, CDC officials said.
For months, Vanderbilt University researcher Dr. James Crowe has been desperately seeking access to the blood of U.S. Ebola survivors, hoping to extract the proteins that helped them overcome the deadly virus for use in new, potent drugs. His efforts finally paid off in mid-November with a donation from Dr. Rick Sacra, a University of Massachusetts physician who contracted Ebola while working in Liberia. The donation puts Crowe at the forefront of a new model for fighting the virus, now responsible for the worst known outbreak in West Africa that has killed nearly 7,000 people.
Abortion is becoming ever rarer in the United States. On Friday, the Centers for Disease Control and Prevention released its latest survey of abortion in the United States. The CDC tallied 730,322 abortions in 2011, the smallest number in almost 40 years. CDC’s numbers are probably an under-count. Other surveys suggest that the number for 2011 was slightly larger than 1 million. But if the precise number of abortions is uncertain, the trend is not. The incidence of abortion in the United States sharply rose in the 1970s and 1980s, reached a peak in 1990, and has tumbled by nearly half over the past two decades.
Over the summer, as it became clear that the Ebola outbreak in West Africa was one of the worst public-health emergencies in recent memory, executives at Merck met at the company’s New Jersey headquarters to figure out how to respond. Public-health organizations were also getting in touch with people at Merck, asking for help. At several meetings, the executives cycled through the possibilities: Should they donate medicines? Financially support the relief efforts? Help to develop treatments for Ebola?
Videos on Georgia